Last reviewed · How we verify
Placebo of Aripiprazole
Placebo of Aripiprazole is a Small molecule drug developed by Otsuka Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Control arm in phase 3 clinical trials of aripiprazole.
This is a placebo control formulation with no active pharmacological mechanism.
This is a placebo control formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials of aripiprazole.
At a glance
| Generic name | Placebo of Aripiprazole |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo of aripiprazole contains no active drug substance and produces no direct pharmacological effect. It is used as a control arm in clinical trials to assess the efficacy of the actual aripiprazole treatment by comparison against a non-active intervention, allowing researchers to distinguish true drug effects from placebo response.
Approved indications
- Control arm in phase 3 clinical trials of aripiprazole
Common side effects
Key clinical trials
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Dopamine and Sensorimotor Function in Stuttering (PHASE1)
- Aripiprazole in Body Focused Repetitive Behaviors (PHASE2)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (PHASE2)
- Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (PHASE1)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Aripiprazole CI brief — competitive landscape report
- Placebo of Aripiprazole updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI